CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 ...

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...

Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cancer via a revised deal that ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs. The proceeds will help the former Fierce 15 ...

AI-infused drug developer Recursion Pharmaceuticals has hired Najat Khan, Ph.D., as chief commercial officer and head of R&D. She joins from Johnson & Johnson where she was chief data science officer ...